Efgartigimod alfa is a Recombinant Protein owned by Argenx, and is involved in 41 clinical trials, of which 16 were completed, 18 are ongoing, and 7 are planned.

Efgartigimod alfa (ARGX-113) clears and degrades circulating disease-causing immunoglobulin G (IgG) antibodies by binding to the neonatal Fc receptor (FcRn) which is responsible for controlling the half-life of IgG antibodies. The IgG mediated activation of complement and IgG Fc receptors are important defense mechanisms of the innate immune system. However, the same mechanisms are implicated in the severe and harmful inflammation, when IgG antibodies react with self-antigens in tissues. IgGs that do not bind to FcRn enter the lysosomal pathway and are degraded.

The revenue for Efgartigimod alfa is expected to reach a total of $77.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Efgartigimod alfa NPV Report.

Efgartigimod alfa is originated and owned by Argenx. Zai Lab is the other company associated in development or marketing of Efgartigimod alfa.

Efgartigimod alfa Overview

Efgartigimod alfa-fcab (Vyvgart) is a human IgG1 antibody fragment. It is formulated as solution for infusion for intravenous route of administration. Vyvgart is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive and membranous glomerulonephritis (membranous nephropathy), lupus nephritis and Sjogren's syndrome and COVID-19 mediated postural orthostatic tachycardia syndrome.

It is also being developed in subcutaneous formulation for the treatment of myasthenia gravis, primary membranous nephropathy, pemphigus vulgaris, immune-mediated necrotizing myopathy, anti-synthetase syndrome and dermatomyositis, polymyositis, immune thrombocytopenia, CIDP using ENHANZE technology platform.

Argenx Overview

Argenx is an immunology company that focuses on the development of human antibodies. The company is primarily developing products for autoimmune diseases. Its key product includes VYVGART, a neonatal Fc receptor blocker, which is used to treat generalized myasthenia gravis in adults which are anti-acetylcholine receptor (AChR) antibody positive. The company’s pipeline products include Efgartigimod, ARGX-117, Cusatuzumab, ARGX-118, ARGX-119 and ARGX-120. Argenx in partnership with Leo Pharma, AgoMab, AbbVie and Staten has been licensed to develop products such as ARGX-112, ARGX-114 and ARGX-115. The company develops antibodies using its proprietary technology platforms such as NHance, simple antibody technology, and others. It operates offices in the Netherlands, the United States, Japan, Switzerland and Belgium. Argenx is headquartered in Breda, the Netherlands.

The company reported revenues of (US Dollars) US$497.3 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$41.2 million in FY2020. The operating loss of the company was US$348.8 million in FY2021, compared to an operating loss of US$477.6 million in FY2020. The net loss of the company was US$408.3 million in FY2021, compared to a net loss of US$608.5 million in FY2020. The company reported revenues of US$138 million for the third quarter ended September 2022, an increase of 39.9% over the previous quarter.

Quick View – Efgartigimod alfa

Report Segments
  • Innovator (NME)
Drug Name
  • Efgartigimod alfa
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Dermatology
  • Genito Urinary System And Sex Hormones
  • Hematological Disorders
  • Immunology
  • Musculoskeletal Disorders
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.